Investors were waiting for the Mankind Pharma IPO for so long that I cannot help but say... 'Dekho wo aa gaya' (English translation - It's finally here).
Yes, the wait is finally over as one of the biggest pharma company's IPO is finally here.
In September 2022, the pharma company filed its papers with the market regulator and ever since then, it was one of the most anticipated IPOs to watch out in 2023.
2023 has not been an easy year for the Indian share markets. Troubles started when Adani - Hindenburg story played out in January 2023 which was followed by the global banking crisis in the US and now the dull prospects of IT companies.
Resultantly, many companies were hesitant about coming out with their offers. With the Mankind Pharma's IPO, this could all change.
Remember, the Tata Technologies IPO is also slated to open in the next couple of months.
With that context out of the way, let's take a look at the key details of Mankind Pharma IPO.
Issue period: 25 April 2023 to 27 April 2023
Issue size: Issue of 40.1 million (m) shares
Type: Offer for sale
Face value: Re 1 per equity share
Price band: Rs 1,026 to Rs 1,080 per equity share
Bid lot: 13 shares and in multiples thereof
Application limit: Minimum one lot maximum fourteen lot for retail investors
Grey market premium (GMP): Rs 90-95 (as of 25 April 2023)
The company has reserved not more than 50% shares of the offer for qualified institutional buyers (QIB). It has reserved not less than 15% for non-institutional buyers (HNI). Hence not less than 35% of shares are available for retail individual investors.
Tentative IPO allotment date: 3 May 2023
Tentative listing date: 8 May 2023
Here are five key details of the IPO.
Mankind Pharma is an Indian multinational pharma company, based in Delhi. The company has products in therapeutic areas ranging from antibiotics to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
It has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the financial year 2022.
During the pandemic, the pharma company's revenue was hit which should come as a surprise because pharma stocks boomed and were the biggest gainers of the Covid-19 rally. However, on a compounded annual growth rate (CAGR) basis, its sales have gone up by 12.2% in the past five years.
Despite incurring high expenses, the company has been able to maintain high profit margins. In financial year 2022, the company's net profit margins suffered despite a 25% rise is total revenue.
Particulars | 31-Mar-22 | 31-Mar-21 | 31-Mar-20 |
---|---|---|---|
Revenues (Rs m) | 79,775.50 | 63,833.50 | 59,756.50 |
Revenue Growth (%) | 25.00% | 6.80% | |
Expenditure Before Tax | 60,174.30 | 47,054.50 | 45,494.50 |
% of Total Income | 75.4 | 73.7 | 76.1 |
Net Profit | 14,529.60 | 12,230.30 | 10,561.50 |
Net Profit Margin (%) | 18.2 | 19.2 | 17.7 |
Net Worth | 63,163.10 | 49,628.90 | 36,715.50 |
Return on Net Worth (%) | 23.3 | 26.8 | 29.6 |
Basic Earnings per share (Rs) | 33.8 | 31.6 | 25.72 |
As per the company's red herring prospectus (RHP), Sun Pharma, Cipla, Zydus Lifesciences, Torrent Pharma, Alkem Laboratories, JB Chemicals and Pharmaceuticals, Eris Lifesciences, Ipca Laboratorires, Abbott India, Dabur India, Procter and Gamble Health, and Zydus Wellness are its listed peers.
Company | Total Income (2022) (Rs m) |
Net Profit | EPS (Basic) (Rs) |
Return on Net Worth (%) |
---|---|---|---|---|
Mankind Pharma | 77,815.6 | 14,529.6 | 35.9 | 23.3 |
Sun Pharma | 386,544.9 | 34,058.0 | 13.6 | 6.8 |
Cipla | 217,633.4 | 25,595.0 | 31.2 | 12.1 |
Zydus Lifesciences | 152,652.0 | 23,264.0 | 43.8 | 26.4 |
Torrent Pharma | 85,080.4 | 7,772.0 | 23 | 13.1 |
Alkem Laboratories | 106,341.9 | 16,803.0 | 137.6 | 19.1 |
JB Chemicals and Pharmaceuticals | 24,242.4 | 3,860.0 | 49.9 | 18.1 |
Eris Lifesciences | 13,470.4 | 4,058.0 | 29.9 | 21.3 |
Ipca Laboratorires | 58,297.9 | 9,110.0 | 34.9 | 16.1 |
Abbott India | 49,192.7 | 10,256.0 | 375.9 | 28.3 |
Glaxosmithkline Pharmaceuticals | 32,780.3 | 3,808.0 | 100 | 63.6 |
Dabur India | 108,886.8 | 17,423.0 | 9.8 | 20.8 |
Procter and Gamble Health | 111,44.1 | 1,925.0 | 116 | 31.2 |
Zydus Wellness | 20,091.0 | 3,089.0 | 48.5 | 6.4 |
So far, 2023 has turned out to be a tough year. Adani group stocks were soaring high before they hit the roadblock because of a report issued by Hindenburg research. Banking stocks also suffered a similar fate.
In 2022, the Nifty Bank index hit life-time highs multiple times, but due to the global banking crisis Indian banking stocks also suffered. It would be safe to say 2023 so far is a year of unexpected events for stock markets.
Coming to Mankind Pharma's IPO, the company is undoubtedly a dominant force to reckon with in its category. A huge market share also suggests that the company is in the maturity stage and the growth phase may be over.
However, the pharma sector is a rapidly evolving sector, with new inventive drugs and healthcare products coming out every now and then.
The company is also subject to stringent regulation which has strong bearing on the overall performance of the company.
Investors should prepare their list of pros and cons before making any investment decision.
Stay tuned to get further updates on this IPO and all upcoming IPOs in the market.
Happy Investing!
Lithium is the new oil. It is the key component of electric batteries.
There is a huge demand for electric batteries coming from the EV industry, large data centres, telecom companies, railways, power grid companies, and many other places.
So, in the coming years and decades, we could possibly see a sharp rally in the stocks of electric battery making companies.
If you're an investor, then you simply cannot ignore this opportunity.
Details of our SEBI Research Analyst registration are mentioned on our website - www.equitymaster.comDisclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...
IPO Price Band is the price range within which investors can bid for the shares. The minimum price is called the floor price and the maximum price is called the cap price.
In case the company revises the price band, the offer period gets extended for at least three additional working days.
Any revision in the price band and the revised offer period, if applicable, is shared by notification to the stock exchanges by issuing a press release and on the websites of the book running lead managers.
GMP stands for grey market premium. It is the amount, over and above the issue price, that traders are willing to pay or ask for to trade IPO shares. The GMP can tell you how an IPO will perform on its listing day.
If you are applying for an IPO, take a look to see what could happen on listing day. But remember GMP shouldn't be the only factor influencing your decision on whether or not to hold or exit the stock.
If you are an investor, then we would say take the GMP with a pinch of salt. A factor as volatile as GMP can't be a deciding factor.
Therefore, you should never apply for an IPO just because it commands a good GMP. You should apply for an IPO because you believe in the company's earning potential. Hence more weightage should be given to the fundamentals of the company.
The best performing IPOs have already delivered outsized returns. So there is a good chance these stocks might be overpriced.
Before you invest your hard-earned money, make sure you check out the valuations first. Studying the business is equally important. One should only invest in fundamentally strong stocks with bright prospects.
Equitymaster requests your view! Post a comment on "Mankind Pharma IPO: 5 Things to Know". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!